The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

Inclusion Criteria: * Peripheral arterial disease * Planned angioplasty or stenting of superficial femoral artery or popliteal artery. Exclusion Criteria: * Patients treated on an emergency basis * Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty) * Planned intervention at site exclusive of superficial femoral artery or popliteal artery * Planned re-stenting at site of prior stent placement * Planned re-angioplasty at site of prior angioplasty * Known inability to tolerate antiplatelet regimen before enrollment * Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center * Current use of prasugrel or ticlopidine * Current use of oral anticoagulation medication * Pregnant patients